Collegium Pharmaceutical Stock Forecast, Price & News

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

Is Collegium Pharmaceutical a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Collegium Pharmaceutical stock.
View analyst ratings for Collegium Pharmaceutical or view top-rated stocks.

How has Collegium Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, COLL shares have increased by 2.2% and is now trading at $17.95.
View which stocks have been most impacted by COVID-19.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,800,000 shares, an increase of 24.7% from the October 31st total of 3,850,000 shares. Based on an average daily volume of 269,900 shares, the short-interest ratio is currently 17.8 days. Currently, 14.3% of the company's shares are short sold.
View Collegium Pharmaceutical's Short Interest.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Collegium Pharmaceutical.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its quarterly earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.22 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.75 by $0.53. The specialty pharmaceutical company had revenue of $78.80 million for the quarter, compared to analysts' expectations of $84.65 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 19.02% and a net margin of 31.77%. Collegium Pharmaceutical's quarterly revenue was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.32 EPS.
View Collegium Pharmaceutical's earnings history.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $330 million-$340 million, compared to the consensus revenue estimate of $340.42 million.

What price target have analysts set for COLL?

3 brokerages have issued twelve-month target prices for Collegium Pharmaceutical's shares. Their forecasts range from $22.00 to $28.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $25.33 in the next twelve months. This suggests a possible upside of 41.1% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the following people:

• Joseph J. Ciaffoni, President, Chief Executive Officer & Director
• Colleen Tupper, Chief Financial Officer & Executive Vice President
• Scott Sudduth, Executive Vice President-Technical Operations
• Richard Malamut, Chief Medical Officer
• Scott Dreyer, Chief Commercial Officer & Executive VP

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

Who are some of Collegium Pharmaceutical's key competitors?

Some companies that are related to Collegium Pharmaceutical include Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), Pacira BioSciences (PCRX), Prothena (PRTA), Cassava Sciences (SAVA), Lyell Immunopharma (LYEL), Harmony Biosciences (HRMY), Indivior (INVVY), Nuvation Bio (NUVB), Xencor (XNCR), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO) and Agios Pharmaceuticals (AGIO).
View all of COLL's competitors.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.28%), Janus Henderson Group PLC (11.86%), Rubric Capital Management LP (7.54%), Renaissance Technologies LLC (3.78%), Principal Financial Group Inc. (3.06%) and Invesco Ltd. (2.78%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical.

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Foundry Partners LLC, Emerald Advisers LLC, Millennium Management LLC, Emerald Mutual Fund Advisers Trust, Rice Hall James & Associates LLC, BlackRock Inc., and Two Sigma Advisers LP. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer, and Shirley R Kuhlmann.
View insider buying and selling activity for Collegium Pharmaceutical or view top insider-selling stocks.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rubric Capital Management LP, South Dakota Investment Council, LSV Asset Management, Summit Global Investments, Renaissance Technologies LLC, SG Americas Securities LLC, and SummerHaven Investment Management LLC.
View insider buying and selling activity for Collegium Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $17.95.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical has a market capitalization of $620.51 million and generates $310.02 million in revenue each year. The specialty pharmaceutical company earns $26.75 million in net income (profit) each year or $2.62 on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

Collegium Pharmaceutical employs 234 workers across the globe.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

Where are Collegium Pharmaceutical's headquarters?

Collegium Pharmaceutical is headquartered at 100 Technology Center Drive, Stoughton MA, 02072.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at (781) 713-3699.